Genomic biomarkers in prostate cancer

Abstract excerpt

Prostate cancer is the most common non-cutaneous cancer among men in the United States. In the last decade there has been a rapid expansion in the field of biomarker assays for diagnosis, prognosis, and treatment prediction in prostate cancer. The evidence base for these assays is rapidly evolving. With several commercial assays available at each stage of the disease, deciding which genomic assays are appropriate...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Molecular Biology Techniques and Applications
• Share to Prostate Cancer Diagnosis and Treatment
• Share to Prostate Cancer Treatment and Research